Hoth Therapeutics (HOTH) Projected to Post Quarterly Earnings on Friday

Hoth Therapeutics (NASDAQ:HOTH) is expected to be announcing its results before the market opens on Friday, March 27th. Analysts expect the company to announce earnings of ($0.1031) per share for the quarter.

Hoth Therapeutics Trading Up 1.4%

Shares of HOTH opened at $0.90 on Thursday. The firm has a market cap of $13.94 million, a P/E ratio of -0.85 and a beta of 0.50. Hoth Therapeutics has a 12 month low of $0.66 and a 12 month high of $2.12. The stock’s 50 day moving average is $0.98 and its two-hundred day moving average is $1.21.

Hedge Funds Weigh In On Hoth Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in HOTH. Geode Capital Management LLC boosted its stake in shares of Hoth Therapeutics by 8.0% in the second quarter. Geode Capital Management LLC now owns 122,575 shares of the company’s stock worth $143,000 after acquiring an additional 9,071 shares during the last quarter. Lido Advisors LLC acquired a new position in Hoth Therapeutics in the 3rd quarter valued at $32,000. Kestra Private Wealth Services LLC purchased a new position in Hoth Therapeutics in the 3rd quarter valued at $51,000. Virtu Financial LLC purchased a new position in Hoth Therapeutics in the 3rd quarter valued at $184,000. Finally, Citadel Advisors LLC acquired a new stake in Hoth Therapeutics during the 3rd quarter worth $232,000. Hedge funds and other institutional investors own 7.08% of the company’s stock.

Wall Street Analyst Weigh In

HOTH has been the topic of a number of recent analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Hoth Therapeutics in a research report on Monday, December 22nd. Wall Street Zen raised shares of Hoth Therapeutics to a “sell” rating in a report on Saturday, March 7th. Finally, D. Boral Capital restated a “buy” rating and set a $5.00 price objective on shares of Hoth Therapeutics in a research report on Wednesday. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Hoth Therapeutics presently has an average rating of “Hold” and an average price target of $5.00.

About Hoth Therapeutics

Hoth Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the acquisition, licensing and development of novel therapies for dermatological, central nervous system and other debilitating conditions. The company’s strategy emphasizes in-licensing late preclinical or early clinical assets with promising pharmacological profiles and leveraging formulation science to optimize delivery. Core to its approach is the design of topical and localized administration platforms intended to enhance drug penetration, sustain release and reduce systemic exposure.

Hoth’s development pipeline encompasses multiple candidate programs addressing high-unmet-need areas such as atopic dermatitis, epidermolysis bullosa and oral mucositis.